| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633 | |
| Description | CD19 molecule | |||||
| GTO ID | GTC3680 |
| Trial ID | NCT06152172 |
| Disease | Idiopathic Inflammatory Myopathy | Diffuse Cutaneous Systemic Sclerosis | Systemic Lupus Erythematosus | Vasculitis |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KYV-101 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | CARTIMMUNE: A Single-Center Study of Patients With Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV 101) |
| Year | 2024 |
| Country | United States |
| Company sponsor | David Porter |
| Other ID(s) | 855064 - CARTIMMUNE |
| Cohort 1 | |||||||||||||
|
|||||||||||||